MariMed Launches Nature’s Heritage ‘LIVE Flower’
MariMed, Inc. (OTCQX: MRMD) (CSE:MRMD) launched Nature’s Heritage “LIVE Flower”.
Jaguar Health Seeks FDA Nod For Cholera Candidate Study
Jaguar Health (NASDAQ: JAGX) has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for its subsidiary Napo's NP-300 drug product candidate for the symptomatic relief of diarrhea from cholera.
Nextleaf Q3 Revenue Grows 83% YoY, Majority Of Revenue From Glacial Gold
Nextleaf Solutions Ltd. (OTCQB: OILFF) (CSE:OILS) (FSE:L0MA) released its Q3 financial results for the quarter ended June 30, 2022, revealing revenue of $1.2 million, an increase of 83% compared to revenue of $655,861 in Q3 2021.
Single-Stock ETFs Would Let Bears Bet Against AMC, Tilray And Other Meme Stocks: What Investors Should Know
Investors can soon short all their favorite meme stocks with the immunity offered by an exchange-traded fund.
What Happened: Rex Shares is planning to add 10 new series of inverse single stock ETFs, mostly meme stocks, Form N1-A filed by funds’ advisor Tidal ETF Trust II late Monday showed.
What Stocks Have ETH On Their Books Ahead Of The Merge?
Ethereum's (CRYPTO: ETH) long-awaited “Merge” is expected to occur around Sept. 15, and is heralding fresh interest for the platform as it transitions to proof of stake from proof of work.
GABY Q2 Revenue Drops 26% YoY, Here Is What You Need To Know
GABY Inc. (OTCQB: GABLF) (CSE:GABY) Q2 2022 revenue was $5.2 million, which after adjustment for the closure of GABY's wholesale distribution business, is down 26% from $7.1 million in Q2 2021.
Q2 2022 Financial & Operational Highlights
Outlook Therapeutics Shares Pop After Filing US Application For Its Lead Eye Disease Candidate
Outlook Therapeutics Inc (NASDAQ:OTLK) has re-submitted its marketing application to the FDA, seeking approval for ONS-5010 for wet age-related macular degeneration…
Connect Biopharma’s Candidate For Skin Disease-Associated Itch Shows Encouraging Safety Profile
Connect Biopharma Holdings Limited (NASDAQ:CNTB) has completed its first-in-human Phase 1 study of CBP-174 in healthy adults. CBP-174, a highly selective,…
Cansortium Q2 Revenue Grows 36% YoY, What About Adjusted EBITDA?
Cansortium Inc. (OTCQX: CNTMF) (CSE:TIUM.U), a vertically-integrated cannabis company operating under the Fluent brand, released its financial results for the second quarter ended June 30, 2022, revealing revenue increased 36% to $22.4 million compared to $16.5 million in Q
TuSimple Moves Closer to China Exit Ramp as Questions Loom on U.S. Commercialization
Key Takeaways:
China’s largest private auto group may acquire TuSimple’s Asia-Pacific business, allowing it to cut its China ties and alleviate U.S. national security concerns
The company’s commercialization timeline has been thrown into doubt following an April accident that raised safety concerns